Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1:15:1289630.
doi: 10.3389/fpsyt.2024.1289630. eCollection 2024.

A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression

Affiliations

A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression

Gianna Capodilupo et al. Front Psychiatry. .

Abstract

Introduction: Despite the development of many successful pharmaceutical interventions, a significant subset of patients experience treatment-resistant depression (TRD). Ketamine and its derivatives constitute a novel therapeutic approach to treat TRD; however, standard tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) are still being used to measure symptoms and track changes.

Methods: The aim of this study was to review item-level differences between rate of data change (MADRS score) and rater-weighted perception of the most useful items for assessing change in symptoms while remotely conducting the 10-item version of the MADRS in TRD in a clinical trial of rapid-acting antidepressants. Two studies of rapid-acting antidepressants in the treatment of TRD were used to identify item-scoring trends when MADRS is administered remotely and repeatedly (733 subjects across 10 visits). Scoring trends were evaluated in tandem to a rater survey completed by 75 raters. This was completed to gain insight on MADRS items' perceived level of helpfulness when assessing change of symptoms in rapid-acting antidepressant trials.

Results: MADRS items 'Reduced sleep', 'Apparent sadness', and 'Pessimistic thoughts' were found to have the greatest average data change by visit, while raters ranked 'Reported sadness', 'Lassitude' and 'Apparent sadness' as the most helpful items when assessing symptom change.

Discussion: The diversion between rate of data-change ranking and rater perception of helpfulness could be related to difficulty in assessing specific items, to the novel treatment itself, and/or to the sensitivity to symptom change to which raters are accustomed in traditional antidepressant treatments.

Keywords: MADRS = Montgomery-Asberg depression rating scale; depression; rapid acting antidepressants; rater perception; structured interview guide for the MADRS (SIGMA).

PubMed Disclaimer

Conflict of interest statement

GC, RB and SN are employed by WCG Clinical Endpoint Solutions. AM is a contractor of WCG Clinical Endpoint Solutions and a part-time employee of Whanganui District Health Board, Whanganui, NZ. MO is employed by WCG Clinical Endpoint Solutions; has received royalties from Pearson Inc. from sales of the PANSS Manual; and has received past grant funding from NIH, Brain & Behavior Foundation, the Stanley Medical Research Institute, and the Qatar National Research Fund. The reviewer WL declared a past co-authorship with the author MO to the handling editor.

Figures

Figure 1
Figure 1
Ranking of MADRS items according to rater perception and data change. aRanking by data change: ranking from tenth position to first position correlates with the average rate of data change between visits, with first position representing the MADRS item with the highest rate of symptom change according to data. bRanking by rater perception: ranking from tenth position to first position correlates with the degree of helpfulness in assessing symptoms of depression, with first position representing the MADRS item perceived as the most helpful when assessing symptom change.

Similar articles

Cited by

References

    1. Food & Drug Administration . FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. (2019).
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. (1979) 134:382–29. doi: 10.1192/bjp.134.4.382 - DOI - PubMed
    1. First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. (2013) 201(9):727–9. doi: 10.1097/NMD.0b013e3182a2168a - DOI - PubMed
    1. World Health Organization . Depression and other common mental disorders: global health estimates (No. WHO/MSD/MER/2017.2) (2017). Available online at: https://apps.who.int/iris/handle/10665/254610 (Accessed September 5, 2023).
    1. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. (2002) 34:13–25. doi: 10.1016/S0896-6273(02)00653-0 - DOI - PubMed

LinkOut - more resources